NCT01113476 is a Phase 1 clinical trial of Nab-paclitaxel in Advanced Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT01113476?

NCT01113476 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01113476?

Interventions in NCT01113476: Nab-paclitaxel, Bevacizumab, Gemcitabine.

What condition does NCT01113476 study?

NCT01113476 studies Advanced Cancer.

Is NCT01113476 still recruiting?

NCT01113476 is currently completed. Last updated 2 September 2022.

Last reviewed 2022-09-02 · How we verify

NCT01113476

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

Completed Phase 1 Last updated 2 September 2022

What this trial tests

Phase 1 trial testing Nab-paclitaxel in Advanced Cancer in 176 participants. Completed in 12 August 2022.

Timeline

27 April 2010

Primary endpoint
12 August 2022

12 August 2022

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	176
Start date	27 April 2010
Primary completion	12 August 2022
Estimated completion	12 August 2022
Sites	1 location across United States

Drugs / interventions tested

Nab-paclitaxel (nab-paclitaxel) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to find the highest tolerable dose of the combination of Abraxane (nab-paclitaxel), Gemzar (gemcitabine), and Avastin (bevacizumab) that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
Sen S, Kato S, Agarwal R, Piha-Paul S, et al · · 2018 · cited 6× · PMID 29695765 · DOI 10.1038/s41416-018-0068-z

Verify or expand the search:

Other trials of Nab-paclitaxel

Trials testing the same drug.

NCT07253662 — Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Aden · Phase 1 · recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
NCT07283705 — A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer · Phase 2 · recruiting
NCT07524257 — ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC · Phase 3 · not yet recruiting
NCT07063745 — A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab a · Phase 2, PHASE3 · recruiting

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01113476 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 2 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01113476.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing